Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease

Clint Piper and William R. Drobyski

1 Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, United States, 2 Department of Medicine, Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI, United States

Graft vs. host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Damage to the gastrointestinal (GI) tract from acute GVHD is a particularly serious event that can result in significant morbidity and mortality. Proinflammatory cytokines play a critical role in the pathophysiology of intestinal GVHD, in part by activating donor T cell populations which subsequently induce tissue damage. In this review, we summarize pre-clinical data derived from experimental murine models that have examined the role of inflammatory cytokine pathways that play critical roles in the pathophysiology of GVHD of the GI tract. Specific areas of focus are on STAT 3-dependent cytokines (e.g., IL-6, IL-23, and IL-21), and members of the IL-1 cytokine family, both of which have been shown to induce pathological damage within the GI tract during this disease. We also review established and ongoing efforts to translate these pre-clinical findings into the clinic in an effort to reduce morbidity and mortality due to this complication.

Keywords: graft vs. host disease, inflammatory cytokines, allogeneic hematopoietic stem cell transplantation, gastrointestinal tract, mouse models

GRAFT vs. HOST DISEASE

Graft-vs.-host disease (GVHD) is the major complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT) and is the leading cause of transplant-related mortality (1, 2). Mature T cells, which are present in the donor stem cell graft, are instrumental in the development of GVHD in HSCT recipients (1, 2). These pathogenic T cells are activated and clonally expand in response to recognition of a cognate recipient-derived peptide on an antigen presenting cell (APC), mounting an adaptive immune response against healthy recipient tissues. Current evidence in the literature suggests that two phases of antigen presentation occur (3). GVHD is initiated by recipient hematopoietic and non-hematopoietic APCs by a process termed direct alloantigen presentation (4, 5). Following the elimination of recipient-derived APCs post-transplantation, donor-derived APCs sustain GVHD by presenting recipient-derived peptides through the indirect pathway (6–9). Studies have revealed that the most important donor-derived APCs in this process are classical dendritic cells (7, 9).

GVHD has been divided into two phases, termed acute and chronic, which are distinguishable based on the timing of onset as well as unique clinical and pathological manifestations...
(10–12). During the acute phase, which is responsible for significant mortality (13), GVHD targets a restricted set of organs including the skin, gastrointestinal (GI) tract, lung, and liver (1, 2, 4). Compelling data in experimental models have shown that the GI tract plays a primary role in the propagation of this disease (14, 15). Damage to the gastrointestinal mucosa from the conditioning regimen results in the release of damage- and pathogen-associated molecular patterns (DAMPs and PAMPs) (16, 17), which activate cells of the innate immune system through the ligation of pattern recognition receptors (PRRs) (2). This ultimately leads to the generation of clonally-expanded alloreactive T cells which mediate further damage, creating an inflammatory cascade (18). From a clinical perspective, involvement of the GI tract is a major cause of morbidity and can result in significant complications including protracted diarrhea, requirement for parenteral nutrition, and infectious complications due to translocation of bacteria across a damaged mucosal barrier (19). Given the pivotal role that the GI tract plays in acute GVHD biology, strategies designed to reduce inflammation in this target organ have the potential to significantly decrease morbidity and mortality associated with this disease.

STAT3 SIGNALING IN GVHD OF THE GI TRACT

During the formation of an immune response, the transduction of signals from the T cell receptor, costimulatory ligands, and cytokines into the nucleus is required for the differentiation of naive T cells into effector lineages. During GVHD, these effector alloreactive cells are then able to secrete inflammatory cytokines and acquire cytotoxic capability, leading to tissue damage. Signal transducer and activator of transcription (STAT) proteins are responsible for much of these gene expression changes as a result of signaling through cytokine receptors. Upon ligation of a cytokine to its receptor, Janus kinases (JAKs) bind to the cytoplasmic domain of the receptor and become active, phosphorylating the appropriate STAT proteins, which then dimerize and translocate to the nucleus where they execute their function in driving transcriptional changes (20). Of these STAT proteins, STAT3 is particularly important in T cell pathogenicity during GVHD (21). In fact, treatment with a small molecule that inhibits STAT3 phosphorylation (22) or transplantation with STAT3-deficient T cells (21) significantly reduced GVHD-related mortality and pathological damage within the colon, providing support for the premise that STAT3-defepend cytokines play a prominent role in the induction of inflammation within this tissue site. Abrogation of STAT3 signaling was associated with a reduction in donor effector T cells with a corresponding increase in the number of regulatory T cells (Tregs). These results suggested that the STAT3 signaling pathway plays a critical role in balancing the effector and regulatory arms of the immune system within the context of GVHD. This basic premise has been confirmed in vitro using human cells where small molecule inhibition of STAT3 signaling suppressed alloreactive T cell proliferation while enhancing expansion of induced Tregs (iTregs) (23). In addition, CD4+ T cell STAT3 activation has been associated with an increase in Treg17 cells and corresponding pathological damage within the GI tract in patients (23).

In contrast to the proinflammatory nature of STAT3 signaling in alloreactive T cells, expression of STAT3 in recipient myeloid cells was found to exacerbate GVHD (24). Notably, this analysis was limited to LysM-expressing cells, which are predominantly of the macrophage/monocyte lineage. While this study did not explore a mechanism for why STAT3 signaling in recipient myeloid cells elicits a paradoxical anti-inflammatory effect, the authors did note an increase in the number of donor CD4+ and CD8+ T cells in the spleen and an elevation in serum IFN-γ and IL-17 in LysM-Cre STAT3−/− recipients compared to WT recipients, suggesting that this subset of recipient myeloid cells might indirectly regulate donor T cell responses. Interestingly, deficiency in donor myeloid cells had no impact on overall GVHD severity (24). Thus, the proinflammatory effects of STAT3 signaling appear to be mediated through T cells and not myeloid cell populations. The potential clinical significance of these observations derives from the fact that a number of the inflammatory cytokines that have been implicated in the pathophysiology of GVHD, specifically within the gastrointestinal tract, use STAT3 as part of their signaling pathway, and therefore are amenable to blockade with appropriate and specific antibodies. The STAT-dependent cytokines which have been most critically examined with respect to GVHD within the GI tract are IL-6, IL-23, and IL-21.

INTERLEUKIN 6

IL-6 is a proinflammatory cytokine that is crucial in initiating a Th17 immune response. In the presence of IL-6 and TGF-β, naive T cells are able to differentiate into cells of the Th17 lineage, whereas in the absence of this cytokine, these same cells are directed to become Tregs (25, 26). Specifically, TGF-β-induced Foxp3 is able to inhibit the transcriptional activation of RORγt which prevents the differentiation of Th17 cells from naive CD4+ T cells (27). Thus, IL-6 appears to have a pivotal role in facilitating inflammatory responses by the immune system. In experimental murine studies, IL-6 and soluble IL-6R levels have both been shown to be increased in the gastrointestinal tract during GVHD (28). Moreover, blockade of IL-6 signaling by the administration of an antibody that binds to the IL-6 receptor significantly reduces GVHD-associated mortality and, specifically, pathologic damage within the colon (28–30). In one study (28), this was attributed to a significant increase in the absolute number of Tregs that was due to augmentation of both thymic-dependent and thymic-independent Treg production. Notably, when GVHD protection was dependent solely upon the ability to generate iTregs, blockade of IL-6 signaling resulted in a reduction in GVHD severity only within the colon (30). These results support the premise that IL-6 has an important role in mediating GVH responses within this tissue site, and that inhibition of this signaling pathway serves to recalebrate the effector and regulatory arms of the immune system in the GI tract. It should be noted that augmented Treg reconstitution
has not been observed in all studies (29), although this may be due, in part, to a more abbreviated anti-IL-6R antibody administration schedule that did not provide sufficient IL-6 blockade to positively affect Treg regeneration. The requirement for more protracted anti-IL-6R antibody administration to observe robust Treg reconstitution is supported by findings in a murine sclerodermatous chronic GVHD model (31).

The potential efficacy of IL-6 blockade for the treatment and prevention of GVHD has also been examined in humans. This is due to the availability of tocilizumab which is a humanized anti-IL-6R antibody that has been FDA-approved for the treatment of patients with rheumatoid and juvenile arthritis (32, 33). Off label use of tocilizumab has therefore been possible in HSCT patients. Initial studies using tocilizumab have been in patients with steroid refractory (SR) GVHD. A total of three studies comprising 31 patients have reported results on the use of tocilizumab for the therapy of SR acute GVHD (34–36). In nearly all patients (i.e. 30/31), treatment was instituted for disease involving the lower GI tract. In two of the three studies, response rates (PR and CR) were quite similar (67 and 69%, respectively). In a third trial, however, responses were observed in only 44% of patients and were short-lived. One potential explanation for the discrepancy in these results is that the majority of patients in this latter trial had concurrent liver GVHD, and tocilizumab has not been shown in any study to have any efficacy for the treatment of disease in the liver. The reasons for this are not entirely clear, although the fact that one of the primary side effects of tocilizumab is transaminitis suggests that this agent may induce some degree of liver inflammation which could be deleterious in the setting of concurrent liver GVHD.

Inhibition of IL-6 has also been examined for the prevention of acute GVHD in allogeneic HSCT patients. The first report was by Kennedy et al. (37) who treated 48 patients (median age 48) with a single dose of tocilizumab on the day prior to transplantation in addition to standard immune suppression consisting of tacrolimus and methotrexate. The primary end point of the study was grade 2–4 acute GVHD at day 100. Conditioning was with either total body irradiation and cyclophosphamide (myeloablative) or fludarabine and melphalan (reduced intensity) and patients were transplanted with stem cell grafts from either HLA-matched sibling or matched unrelated donors. The incidence of grades II-IV and III-IV acute GVHD at day 100 was 12 and 3%, respectively, which was lower than historical controls, although this was not a randomized trial nor were the patients demographically matched to a historical control population from the database of the Center for International Blood and Marrow Transplant Research consisting of patients who were demographically matched for age, performance status, conditioning regimen, disease, and donor type, but who had received only tacrolimus and methotrexate for GVHD prophylaxis. This analysis revealed a lower cumulative incidence of grades II-IV acute graft vs. host disease (17 vs. 45%) and a significant increase in grades II-IV acute graft vs. host disease-free survival at 6 months (69 vs. 42%) in patients who were treated with tocilizumab, tacrolimus, and methotrexate. Collectively, these studies provided evidence that inhibition of IL-6 signaling had efficacy for the prevention of GVHD in the GI tract in allogeneic HSCT patients.

**INTERLEUKIN 23**

IL-23 is a member of the IL-12 family, signals through STAT3, and is secreted by DCs, as well as other APCs such as macrophages and monocytes (41). This cytokine shares a p40 subunit with IL-12, but also contains an IL-23-specific p19 component. The p19/p40 complex binds to a heterodimer of IL-12Rβ1, which is shared with the IL-12 receptor and a unique IL-23 receptor subunit that together is present on memory/activated T cells, DCs and macrophages (42). Early studies demonstrated that IL-23 plays a critical role in disorders such as experimental allergic encephalomyelitis (EAE) (43), collagen-induced arthritis (44), and inflammatory bowel disease (45) implicating this cytokine as a pivotal mediator in the pathogenesis of inflammatory disorders and autoimmunity. Preclinical murine BMT studies have demonstrated that IL-23 has a selective role in the promotion of inflammation within the colon during acute GVHD. In addition, this cytokine also functions as a critical mediator linking mucosal injury and LPS translocation that occurs as a consequence of the conditioning regimen to subsequent proinflammatory cytokine production and GVHD-associated pathological damage (46, 47). In these murine models, transplantation of IL-23-deficient marrow grafts or the administration of a p19-specific antibody resulted in
a significant amelioration in the severity of acute GVHD. This was shown to be due to the preferential reduction in colonic GVHD-induced pathology, accompanied by a decrease in proinflammatory cytokine production within this target organ. Donor, as opposed to host, APC production of IL-23 was demonstrated to be crucial for inducing GVHD-associated inflammation in the colon. These findings established that IL-23 has a novel organ-specific role in GVHD biology within the context of a broader systemic inflammatory disorder. Further mechanistic studies revealed that the proinflammatory effects of IL-23 were mediated at least in part by IFN-γ, not IL-17, and that an intact upstream LPS/TLR4 signaling pathway was required for IL-23-mediated colonic inflammation. Moreover, blockade of this pathway did not abrogate the graft vs. leukemia effect when tested in both acute and chronic models of leukemia (46).

More recent studies have shown that blockade of the IL-23 receptor using either genetic or antibody-based approaches similarly protect mice from lethal GVHD and pathological damage in the colon (47). In the course of these studies, a unique colitogenic CD4+ T cell population was identified that constitutively expresses the β2 integrin CD11c, has a biased central memory phenotype, possesses innate-like properties by gene expression analysis, and has augmented expression of the gut-homing molecules, α4β7 and CCR9. Adoptive transfer of these cells resulted in increased overall mortality, proinflammatory cytokine production, and pathology specifically in the colon. The pathogenicity of these cells was critically dependent upon co-expression of the IL-23 receptor. The fact that these CD4+ T cells possess an innate-like transcriptional signature suggests that they are positioned at the interface of the innate and adaptive immune systems where they are able to mediate early inflammatory events during GI tract GVHD.

There are currently two p19-specific antibodies (i.e., guselkumab and tildrakinumab) that have received FDA approval for the therapy of psoriasis (48, 49). However, specific blockade of the IL-23 signaling pathway has not been examined for the prevention or treatment of GVHD in humans. Ustekinumab which binds to the p40 subunit and thereby inhibits both IL-12 and IL-23 has been administered to patients for the prevention of GVHD in a randomized, placebo-controlled study (50). The results of this trial showed that patients treated with Ustekinumab had no difference in the incidence of grades 2–4 acute or chronic GVHD, and there was no specific protective effect on the severity of GVHD within the GI tract. Interestingly, despite the lack of effect on GVHD, there was a significant reduction in transplant-related mortality which translated to an improvement in survival. However, since the trial was not powered to assess these clinical outcomes and therefore were not the primary endpoints of the trial, the significance of these findings is not entirely clear.

**INTERLEUKIN 21**

IL-21 is produced by CD4+ T cells, CD8+ T cells, and NKT cells, while the receptor for IL-21 is expressed on T cells, B cells, NK cells, dendritic cells macrophages, and epithelial cells (51). The role of IL-21 in the biology of GVHD has been examined in a number of murine transplantation models (52–55). A common finding in all of these studies has been that blockade of IL-21 signaling by either antibody-based strategies or genetic approaches is able to significantly reduce the severity of GVHD. In some instances, this was shown to be due to an increase in the reconstitution of Tregs accompanied by a commensurate reduction in the expansion of donor effector T cells, suggesting that blockade of IL-21 signaling recalibrates the effector and regulatory arms of the immune system, similar to IL-6 blockade. Notably, several studies have confirmed that blockade of IL-21 signaling results in decreased pathological damage specifically within the GI tract (52–55). More recently, tissue from the GI tract of patients with active GVHD also revealed increased IL-21 expression in mononuclear cells in the colon when compared to samples obtained from patients with no GVHD (56), suggesting that IL-21 may play a role in gastrointestinal GVHD in humans as well. As of yet, however, there have been no trials examining whether blockade of IL-21 signaling is able to reduce the severity of GVHD in humans.

**INTERLEUKIN 1 FAMILY MEMBERS**

Interleukin-1 (IL-1) was one of the first cytokines described and was named for the soluble product of macrophages during inflammation (57). Since then, IL-1 has been discovered to be not a single gene product but a family of cytokines (58), collectively referred to as the “IL-1 superfamily” (59, 60). Most of the genes in the IL-1 family are clustered together on the same chromosome, likely attributable to a gene duplication event that is evident in their similarity in sequence, structure, and function (61). IL-1 family cytokines direct a host of events in the immune system ranging from acute inflammatory processes initiated by the cells of the innate immune system (57), to T cell differentiation (62), to the regulation of inflammation (63, 64). In this section, we will focus on the “classical” IL-1 cytokines (IL-1β and IL-1β) as well as the IL-1 receptor antagonist (IL-1RA), which binds the IL-1 receptor and blocks binding of other ligands but elicits no signaling itself (64). Furthermore, we will discuss new insights into the role of IL-33, another IL-1 family member, and its cognate receptor ST2 in mediating inflammation in the GI tract during GVHD.

**INTERLEUKIN 1**

A role for the IL-1 family in the biology of GVHD was first postulated in 1991 when increased levels of IL-1α mRNA was detected in the skin of GVHD recipients in an MHC-matched, minor antigen mismatched murine transplant model (65). In addition, the administration of a recombinant human IL-1Ra was found to significantly increase survival in transplant recipients (66), supporting a role for this cytokine in the pathophysiology of this disease. Subsequent studies yielded more conflicting results, raising the issue as to whether this observed variability might, to some extent, be model-specific (66, 67). These preclinical
studies, however, did lay the foundation for human trials testing the efficacy of IL-1 blockade which were conducted in patients with steroid-refractory GVHD. In a phase I/II trial, which involved a 7 day continuous infusion of recombinant IL-1Ra, 10 out of 16 patients had an overall reduction in GVHD grade, including 8 out of 11 patients with GI-tract involvement who showed improvement (68). In another phase I/II trial using a recombinant IL-1 decoy receptor, eight of 14 patients had an overall reduction in GVHD grade, with 2 of 6 patients with GI tract involvement showing organ-specific improvement (69). The largest clinical trial examining anti-IL-1-directed therapy was conducted nearly a decade after the initial observation in murine models (70). This was a double-blind, placebo-controlled trial involving 186 patients in which the study arm consisted of treatment with an IL-1 receptor antagonist for GVHD prophylaxis. The primary endpoints of this study were event-free survival, overall survival, and incidence of GVHD. Unfortunately, patients that received IL-1Ra treatment had no improvement in any of these outcome measures. Notably, recombinant IL-1Ra was administered in the peritransplant period, with IL-1Ra levels in the serum returning to baseline by day 14 (70), before most patients develop acute GVHD. Whether this administration schedule may have been responsible for the lack of any perceived effect is not clear and the ability of IL-1 blockade to prevent GVHD within the GI tract in humans remains unproven.

INFLAMMASOME SIGNALING

With the discovery of the inflammasome (71) there has been renewed interest in the role of IL-1 cytokines in gastrointestinal GVHD. This is due to the fact that the GI tract is a source of innate immune activating pathogen- and damage-associated molecular patterns (15), some of which can cause activation and assembly of the inflammasome. In the case of one particular NLRP3, the ligation of TLR4 by lipopolysaccharide (LPS) causes the up regulation of inflammasome substrates and components such as pro-IL-1β and NLRP3 (72), as well as the deubiquitination and stabilization of NLRP3 (73). As a complementary step, the ligation of the purinergic receptor P2X7 by ATP provides the second step in inflammasome activation, ultimately leading to the assembly of NLRP3 with ASC, cleavage of pro-caspase-1, and caspase-1-mediated conversion of pro-IL-1β to its secreted and biologically active form (73).

Jankovic and colleagues provided the first evidence that the NLRP3 inflammasome is important in the pathophysiology of gastrointestinal GVHD (74). This report showed that in a MHC-mismatched murine model, pretransplant but not post-transplant treatment of mice with an IL-1 receptor antagonist or an IL-1β blocking antibody prevented GVHD. Furthermore, they showed that the NLRP3 inflammasome was required for production of IL-1 in the GI tract and corresponding lethality post-transplant. Biopsies from patients with GVHD had a higher proportion of cleaved (active) caspase-1 staining cells by immunohistochemistry compared to biopsies from transplant patients without GVHD. PBMCs isolated from patients with GVHD produced more IL-1β than those from BMT patients without GVHD and healthy controls. These results provide strong evidence that the NLRP3 inflammasome/IL-1β pathway is involved in the pathogenesis of gastrointestinal GVHD and that further investigation into these pathophysiological mechanisms is warranted to determine whether this will have potential therapeutic implications. In this regard, it is noteworthy that transplantation of microRNA(mir)-155-deficient dendritic cells has also been shown to cause less GVHD in the GI tract due to defective inflammasome activation (75). This observation could potentially be exploited clinically using antagonism administration to inhibit mir-155.

INTERLEUKIN 33/ST2 AXIS

One of the more recently identified pathways in GVHD biology is the IL-33/ST2 axis. IL-33 is a member of the IL-1 superfamily that has been identified as an alarmin and is released during cell injury and necrosis to initiate the immune response (76). IL-33 is produced primarily by a variety of non-hematopoietic cells which include endothelial cells, fibroblasts, and epithelial cells in the intestines and bronchi. Within the GI tract, in particular, IL-33 is expressed by α-SMA+ subepithelial myofibroblasts which have also been termed pericryptal fibroblasts (77). Release of IL-33 leads to binding to its membrane receptor, ST2, which is expressed on a large number of immune cells (i.e., Tbet2 cells, regulatory T cells, type 2 innate lymphoid cells, macrophages, and granulocyte populations) (78). Notably, a soluble form of the receptor, sST2, lacks transmembrane and cytoplasmic domains and serves as a decoy receptor to IL-33, hampering the ability of this cytokine to elicit and effect in target cells (76).

In preclinical studies, IL-33 and sST2 have both been shown to be increased in the blood of mice during GVHD (79, 80). IL-33 is specifically increased in the GI tract where it is produced by non-hematopoietic cells in both murine models and patients with stage IV acute GVHD (79). The mechanism by which the IL-33/ST2 axis manipulates GVHD is complex. Transplant recipients that are deficient for IL-33 are protected from GVHD and administration of IL-33 in the early post transplantation period (days 3–7 post-transplant) was shown to exacerbate this disease (79), suggesting a proinflammatory role. Post-transplant IL-33 administration was associated with reduced survival, higher serum TNF-α, and an increased number of infiltrating intestinal donor T cells (79). Of note, post-transplantation blockade of IL-33 with an sST2-Fc receptor fusion protein also attenuated GVHD. In contrast, peri-transplant IL-33 administration (days −10 to +4) attenuated disease (81). This reduction in GVHD severity was associated with an increase in recipient mST2+ regulatory T cells, a cell population that is able to survive after total body irradiation. A reduction in GVHD was also observed in mice that received peritransplant sST2 blockade, which potentiates the effects of IL-33 due to an inhibition of its decoy receptor (80). Notably, sST2 blockade did not affect expression of mST2 on specific lymphocyte populations, such as Th2 cells and regulatory T cells (80). These data indicate a
The paradoxical role for IL-33/ST2 signaling in GVHD, whereby early treatment of IL-33 downregulates inflammation in the GI tract, whereas administration of IL-33 is proinflammatory once disease has been established. Thus, the pro or anti-inflammatory effects of IL-33 in GVHD appear to be highly schedule dependent. While the reasons for this are still not completely clear, this disparity could be due to differences in cell populations which populate the gastrointestinal tract at various stages post-transplantation. For example, recipient Tregs of which there is an ST2+ subset which can be expanded with peritransplant IL-33 treatment are present early post-transplantation and can suppress GVHD (81). In fact, the depletion of Tregs during peritransplant IL-33 administration results in the loss of protection against GVHD (81). Conversely, IL-33 signaling appears to act primarily on ST2+ conventional T cells later post-transplantation resulting in an exacerbation of the disease (79). The temporal effects of IL-33 in these models may also be, to some extent, dose-dependent, as mice which received IL-33 peritransplant and were protected from GVHD received more than twice the dose over a much longer treatment window (81) than those that received posttransplant IL-33 (79).

In allogeneic HSCT patients, ST2 has emerged as a powerful biomarker that is predictive for GVHD severity in patients. Specifically, biomarker panels obtained early post transplantation which incorporated ST2 have been shown in several studies to be predictive for increased non-relapse-related mortality (82–84). In addition, in one of these studies (83), severe GI tract GVHD was also significantly greater in those patients who were in the cohort with highest levels of ST2. ST2 has also emerged as a critical component of a biomarker panel that has been shown to be predictive for response or lack thereof in steroid refractory acute GVHD (85). This disease carries a particularly high mortality which is typically attributable to disease involving the GI tract which is often the proximate cause of death. To date, there have been no clinical studies which have attempted to interrupt signaling through the IL-33/ST2 pathway in order to reduce inflammation. However, recent efforts to develop small molecule inhibitors that interfere with this pathway has shown promise in murine studies where there has been a reduction in sST2 plasma levels, reduced GVHD, and improved survival (86). Thus, these data provide hope that targeting of this pathway may soon be clinically feasible.

OTHER CYTOKINES

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

GM-CSF was originally characterized and designated as a hematopoietic growth factor which could promote myelopoiesis in the bone marrow. However, more recent studies have demonstrated that GM-CSF is largely redundant in the development of the hematopoietic system as mice deficient in either the cytokine or its receptor have only limited defects in steady-state myelopoiesis (87, 88). Rather, GM-CSF has been implicated as a key signaling molecule which is able to activate the innate immune system in autoimmune and proinflammatory syndromes such as experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis (89). In EAE, for example, GM-CSF is required for the induction of autoimmunity (90, 91) and serves as a conduit between CD4+ T cells and CCR2+ macrophages (92). In the latter cell population, GM-CSF institutes a proinflammatory transcriptional program which facilitates pathological damage within the central nervous system (92). Recently, a role for GM-CSF in GVHD has been posited by Ulrich et al. who described a population of BATF-dependent IL-7Rα+ T cells that produce GM-CSF (93). In this report, which primarily focused on inflammation in the gastrointestinal tract, GM-CSF+/− T cells induced less GVHD in the colon as evidenced by reduced colonooscopy and clinical scores, as well as increased overall survival. This finding was replicated in a MHC-mismatched and haploidentical transplant models by Hughes et al. (94). Interestingly, GVHD was attenuated when GM-CSF receptor deficient bone marrow donors were used, suggesting that the proinflammatory effects of GM-CSF are at least in part mediated through donor myeloid cells. However, a mechanism or specific target myeloid populations for GM-CSF signaling were not definitively established. Thus, further studies are needed to elucidate the full role of this proinflammatory cytokine. Given that mavrilimumab (95), an anti-GM-CSF receptor alpha monoclonal antibody, and MOR103 (96), a humanized anti-GM-CSF antibody, are currently in clinical trials for the treatment of rheumatoid arthritis and multiple sclerosis, respectively, GM-CSF could represent a new target for the prevention of GVHD in the GI tract.

Interferon-Gamma (IFN-γ)

Donor T cells with a Th1 cytokine phenotype have an important role in the pathophysiology of GVHD (1, 2). The signature cytokine of these cells, IFN-γ, has also been demonstrated to induce pathological damage in the GI tract during GVHD. However, inhibition of IFN-γ signaling has divergent effects on GVHD target organs in pre-clinical murine models. Specifically, these studies have shown that mice transplanted with IFN-γ deficient grafts have reduced pathology in the GI tract (14, 97), but rapidly develop an idiopathic pneumonia syndrome (IPS)-like disease early post-transplantation resulting in increased mortality (97–99). The protective effect of IFN-γ is mediated through host non-hematopoietic cells, likely the lung parenchyma itself (97, 99), which inhibit the production of IL-6 by signaling through the IFN-γR (99). In contrast, IFN-γR signaling in T cells appears to be proinflammatory. A reduction in GVHD severity was observed when recipients were transplanted with IFN-γR-deficient T cells (97, 100). Additionally, reduced pathological damage occurred in the GI tract of these recipients without a commensurate increase in tissue damage in the lung (100). This was attributable to reduced expression of the chemokine receptor, CXCR3, which altered trafficking into this tissue site. To date, likely due to the divergent effects observed with inhibition of IFN-γ signaling in these pre-clinical models, there have been no clinical studies targeting this pathway to ameliorate GVHD in the GI tract.
CONCLUSIONS

The GI tract is the target organ which induces the most profound morbidity in patients who develop GVHD after allogeneic HSCT, and is responsible for much of the mortality associated with this disease. Inflammatory cytokines have been shown to play a pivotal role in this process and serve to amplify the pathogenic effects of alloreactive donor T cells. Ongoing research, primarily in murine models, has identified a number cytokines (IL-6, IL-21, IL-23, IL-1, IL-33, GM-CSF) and cytokine pathways (e.g., STAT3 signaling dependent, inflammasome-mediated) that are operative in the pathophysiology of GVHD of the GI tract. Notably, many of these cytokines or specific pathways can be targeted with existing, clinically available antibodies or small molecules designed to inhibit their activity in human transplant recipients. Thus, there is now optimism that the further evolution of this work will lead to the rational development of new strategies designed to reduce the severity of this complication in man and ultimately result in improved overall survival.

AUTHOR CONTRIBUTIONS

CP and WD wrote and edited the manuscript.

FUNDING

This research was supported by grants from the National Institutes of Health (HL064605, HL126166, and HL139008) and by awards from the Midwest Athletes Against Childhood Cancer Fund.

REFERENCES

1. Shlomchik WD. Graft-versus-host disease. *Nat Rev Immunol.* (2007) 7:340–52. doi: 10.1038/nri2000
2. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. *Nat Rev Immunol.* (2012) 12:443–58. doi: 10.1038/nri3212
3. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. *Blood* (2007) 110:9–17. doi: 10.1182/blood-2006-12-022038
4. Shlomchik WD, Couzens MS, Tang CR, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen presenting cells. *Science* (1999) 285:412–5. doi: 10.1126/science.285.5426.412
5. Koyama M, Kuns RD, Olver SD, Wilson YA, Don AL, et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. *Nat Med.* (2012) 18:135–42. doi: 10.1038/nm.2597
6. Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, et al. Donor APCs are required for maximal GVHD but not for GVL. *Nat Med.* (2004) 10:987–92. doi: 10.1038/nm1089
7. Koyama M, Cheong M, Markey KA, Gartlan KH, Kuns RD, Locke KR, et al. Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. *J Exp Med.* (2015) 212:1303–21. doi: 10.1084/jem.20150329
8. Touibai T, Tawara I, Sun Y, Liu C, Nieves E, Evers R, et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. *Blood* (2012) 119:3844–53. doi: 10.1182/blood-2011-10-384057
9. Markey KA, Banovic T, Kuns RD, Olver SD, Don AL, Raffelt NC, et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. *Blood* (2009) 113:5644–9. doi: 10.1182/blood-2008-12-191833
10. Zeiser R, Socie G, Blazar BR. Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. *Br J Haematol.* (2016) 175:191–207. doi: 10.1111/bjh.14295
11. Vriesendorp HM, Heidt PJ. History of graft-versus-host disease. *Exp Hematol.* (2016) 44:674–88. doi: 10.1016/j.exphem.2016.05.011
12. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. *Blood* (2014) 124:374–84. doi: 10.1182/blood-2014-01-514752
13. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulisipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. *Blood* (2014) 124:287–95. doi: 10.1182/blood-2014-01-550566
14. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. *Blood* (2009) 113:2352–62. doi: 10.1182/blood-2008-08-175448
15. Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. *Blood* (2006) 95:2754–9.
16. Wilhelm K, Ganesan J, Müller T, Dür C, Grimm M, Bellhack A, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. *Nat Med.* (2010) 16:1434–8. doi: 10.1038/nm.2242
17. Apostolova L, Zeiser R. The role of purine metabolites as DAMPs in acute graft versus host disease. *Front Immunol.* (2016) 7:439e. doi: 10.3389/fimmu.2016.00439
18. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. *Blood* (1997) 90:2304–13.
19. Naymagon S, Naymagon L, Wong SY, Ko HM, Renteria A, Levine J, et al. Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. *Nat Rev Gastroenterol Hepatol.* (2017) 14:711–26. doi: 10.1038/nrgastro.2017.126
20. O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. *Immunity* (2008) 28:477–87. doi: 10.1016/j.immuni.2008.03.002
21. Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, et al. Stat3 and Erk1/2 phosphorylation are critical for tumor cell alloactivation and graft versus host disease. *Blood* (2008) 112:5254–8. doi: 10.1182/blood-2008-03-147322
22. Betts BC, Veerapathran A, Pidala J, Yu XZ, Ansett C. Stat5 polarization of iTregs and suppresses human T cell alloresponses while preserving CTL activity. *J Leuk Biol.* (2013) 95:205–13. doi: 10.1189/jlb.0313154
23. Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, et al. CD4+ T cell Stat3 phosphorylation precedes acute GVHD and subsequent TH17 tissue invasion correlates with GVHD severity and therapeutic response. *J Leuk Biol.* (2015) 97:807–19. doi: 10.1189/jlb.0315134
24. Nieves EC, Toubai T, Peltier DC, Oravecz-Wilson K, Liu C, Tamaki H, et al. Stat3 expression in host myeloid cells controls graft versus host disease. *J Leuk Biol.* (2016) 95:133–44. doi: 10.1189/jlb.0515134
25. Apostolova L, Zeiser R. The role of purine metabolites as DAMPs in acute graft versus host disease. *Front Immunol.* (2016) 7:439e. doi: 10.3389/fimmu.2016.00439
26. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the TH17 lineage. *Nature* (2006) 441:235–8. doi: 10.1038/nature04753
43. Cua DJ, Sherlock J, Beres A, Hessner MJ, Mihara M, et al. Blockade of interleukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood (2009) 114:981–900. doi: 10.1182/blood-2009-01-197178

29. Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, et al. Blockade of interleukin 23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia responses. Blood (2010) 115:5249–58. doi: 10.1182/blood-2009-11-255422

31. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft versus host disease. J Invest Dermatol. (2012) 132:2752–61. doi: 10.1038/jid.2012.226

28. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, et al. Interleukin 23 rather than interleukin 12 is the critical cytokine for autoimmunne inflammation of the brain. Nature (2003) 421:744–8. doi: 10.1038/nature01355

44. Murphy, CA, Langrish CL, Chen Y, Blumenschein W, McLellanah T, Kastelein RA, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. (2003) 196:1951–7. doi:10.1084/jem.20030896

40. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature (1985) 315:641–7. doi: 10.1038/315641a0

49. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE2): results from two randomized controlled phase 3 trials. Lancet (2017) 390:276–88. doi: 10.1016/S0140-6736(17)31279-5

50. Pidala J, Beato F, Kim J, Betts B, Jim H, Sagats E, et al. In vivo IL-12/IL-23p40 neutralization blocks TH1/TH17 response after allogeneic hematopoietic cell transplantation. Haematologica (2018) 103:531–9. doi: 10.3324/haematol.2017.171199

51. Splotski R, Leonard WJ. The yin and yang of interleukin 21 in allergy, autoimmunity and cancer. Curr Opin Immunol. (2008) 20:295–301. doi: 10.1016/j.coi.2008.02.004

41. Murphy, CA, Langrish CL, Chen Y, Blumenschein W, McLellanah T, Kastelein RA, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. (2003) 196:1951–7. doi:10.1084/jem.20030896

42. Parham C, Sherlock J, Beres A, Hessner MJ, Mihara M, et al. Blockade of interleukin 23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia responses. Blood (2010) 115:5249–58. doi: 10.1182/blood-2009-11-255422

47. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victoria GD, et al. TGF-beta-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORgamma function. Nature (2008) 453:236–40. doi: 10.1038/nature06878

54. Blauvelt A, Papp KA, Griffiths CF, Randazzo B, Wasfy Y, Shen YK., et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blind, placebo and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. (2017) 76:405–17. doi: 10.1016/j.jaad.2016.11.041

48. Blauvelt A, Papp KA, Griffiths CF, Randazzo B, Wasfy Y, Shen YK., et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blind, placebo and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. (2017) 76:405–17. doi: 10.1016/j.jaad.2016.11.041

52. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 198:1951–7. doi:10.1084/jem.20030896

49. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE2): results from two randomized controlled phase 3 trials. Lancet (2017) 390:276–88. doi: 10.1016/S0140-6736(17)31279-5

53. Oh I, Ozaki K, Meguro A, Hatanaka K, Kadowaki M, Matsu H, et al. Altered effector CD4+ T cell function in IL-21R−/− CD4+ T cell-mediated graft versus host disease. J Immunol. (2010) 185:1920–6. doi: 10.4049/jimmunol.0902217

54. Murphy, CA, Langrish CL, Chen Y, Blumenschein W, McLellanah T, Kastelein RA, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. (2003) 196:1951–7. doi:10.1084/jem.20030896

55. Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Clin Exp Immunol. (2000) 121:18–26. doi: 10.1046/j.1365-2249.2000.1210018.x

56. Hippen KL, Bucher KL, Schirm KL, Beato F, Hantana K, Kadowaki M, Matsu H, et al. Altered effector CD4+ T cell function in IL-21R−/− CD4+ T cell-mediated graft versus host disease. J Immunol. (2010) 185:1920–6. doi: 10.4049/jimmunol.0902217

57. Dinarello CA. Immunological and Inflammatory Functions of the Interleukin-1 Family. J Immunol (2003) 170:1739–52. doi:10.4049/jimmunol.1701739
63. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. (2000) 191:313–20. doi: 10.1084/jem.191.2.313
64. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature (1999) 343:336–40. doi: 10.1038/34336a0
65. McCarthy PL, Abhayankar S, Neben S, Newman G, Sief C, Thompson RC, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood (1991) 78:1915–8.
66. Abhayankar S, Gilliland DG, Ferrara JRL. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation (1993) 56:1518–23. doi: 10.1097/00007890-199312000-00004
67. Valliera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. Blood (2017) 129:162–70. doi: 10.1182/blood-2016-08-735324
68. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease. Blood (1994) 83:1342–8.
69. McCarthy PL, Williams L, Harris-Bacile M, Yen J, Przepiorka D, Ippoliti C, et al. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation (1996) 62:626–31. doi: 10.1097/00007890-199609150-00015
70. Antin JH, Weidorf D, Neuber D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood (2002) 100:3479–82. doi: 10.1182/blood-2002-03-0985
71. Martonin F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro-IL-beta. Mol Cell. (2002) 10:417–26. doi: 10.1016/s0959-437x(02)00599-3
72. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert DP, et al. IFN gamma differentially controls the development of idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. (1994) 91:5359–6. doi: 10.1073/pnas.91.12.5592
73. Antin J, Stein JJ, Ganesan J, Bscheider M, Stickel N, Weber FC, Guarda G, et al. Peri-alloHCT IL-33 administration expands recipient T regulatory cells that protect mice against acute GVHD. Blood (2016) 128:427–39. doi: 10.1182/blood-2015-12-684142
74. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft versus host disease based on biomarkers: a multicenter study. Lancet Haematol. (2015) 2:e21–9. doi: 10.1016/s2352-3026(14)00355-0
75. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. (2000) 191:313–20. doi: 10.1084/jem.191.2.313
76. Cayrol C, Girard J-P. Interleukin 33 (IL-33): a nuclear cytokine from the IL-1 family. Cytokine. (2007) 37:39–47. doi: 10.1016/j.cyto.2007.06.017
77. Hodzic Z, Schill EM, Bolock AM, Good M. IL-33 and the intestine: the good, the bad, and the inflammatory. J Immunol. (2015) 194:4135–43. doi: 10.4049/jimmunol.1500244
78. Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber FC, Guarda G, et al. Interferon-gamma controls the development of idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. (1994) 91:5359–6. doi: 10.1073/pnas.91.12.5592
79. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature (2012) 481:278–86. doi: 10.1038/nature10759
80. Lehmann J, Ehmke S, Bittner T, Wollny R, Ley K, Lipp M, et al. Granulocyte-macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA. (1994) 91:5359–6. doi: 10.1073/pnas.91.12.5592
81. Antin J, Weinstein H, Guinan E, McCarthy P, Bierer B, Gilliland D, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood (1994) 84:1342–8.
82. Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature (1991) 343:336–40. doi: 10.1038/34336a0
83. Antin J, Campbell HK, McKenzie BS, Wicks JP, GM-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. (2009) 5:355–9. doi: 10.1038/nrrheum.2009.178
84. Abbate M, Grifoni A, D’Ippolito C, Gamba G, Galli S, Ponzoni M, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. (2013) 210:1899–910. doi: 10.1084/jem.20130399
85. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. (2000) 191:313–20. doi: 10.1084/jem.191.2.313
86. Antin J, Stein JJ, Ganesan J, Bscheider M, Stickel N, Weber FC, Guarda G, et al. Peri-alloHCT IL-33 administration expands recipient T regulatory cells that protect mice against acute GVHD. Blood (2016) 128:427–39. doi: 10.1182/blood-2015-12-684142
CD4+ T-cell–mediated graft-versus-host disease. *Am J Respir Crit Care Med.* (2008) 178:379–88. doi: 10.1164/rccm.200711-1648OC

99. Varelias A, Gartlan KH, Kreijveld E, Olver SD, Lor M, Kuns RD, et al. Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. *Blood* (2015) 125:2435–44. doi: 10.1182/blood-2014-07-590232

100. Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNγR signaling mediates alloreactive T cell trafficking and GVHD. *Blood* (2012) 120:4093–103. doi: 10.1182/blood-2012-01-403196

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Piper and Drobyski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.